X

Trial Profile

A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 30 Nov 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Anastrozole (Primary)
Indications Adenocarcinoma; Advanced breast cancer; Early breast cancer
Focus Adverse reactions; Biomarker; Pharmacogenomic

Most Recent Events

27 Nov 2023 Planned primary completion date changed from 31 Dec 2023 to 31 Dec 2024.
30 May 2023 Planned primary completion date changed from 30 Jun 2021 to 31 Dec 2023.
07 Jun 2022 Results assessing whether GP5 predicts early aromatase inhibitor discontinuation in the racially diverse, presented at the 58th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com